Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desvenlafaxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 9/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CNR1 | P21554 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10491682 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL2053955 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Hydrochloric Acid SCHEMBL10772551 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL4306707 | 0.98 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL4306704 | 0.98 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL34864 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL10772550 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL3277527 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL34863 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL3345158 | 0.97 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114863-A2 | SOLID FORMS COMPRISING (-) O-DESMETHYLVENLAFAXINE AND USES THEREOF | Sepracor Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008103461-A2 | SOLID FORMS COMPRISING (-) O-DESMETHYLVENLAFAXINE AND USES THEREOF | SEPRACOR INC. (US) | 2008-08-28 | — | — | WO | claimed |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| CN-122010945-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-03-31 | — | — | US | disclosed |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-27 | — | — | US | disclosed |
| EP-2240485-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Pharmaceutical Company Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010079046-A1 | PROCESS FOR THE PREPARATION OF DESVENLAFAXINE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | CHEMO IBÉRICA, S.A. (ES) | 2010-07-15 | — | — | WO | disclosed |
| WO-2009138234-A1 | PROCESS FOR THE PREPARATION OF O-DESMETHYLVENLAFAXINE SALTS | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2009-11-19 | — | — | WO | disclosed |
| EP-2119695-A1 | Preparation of O-desmethylvenlafaxine salts | KRKA (SI) | 2009-11-18 | — | — | EP | disclosed |
| EP-2114863-A2 | SOLID FORMS COMPRISING (-) O-DESMETHYLVENLAFAXINE AND USES THEREOF | Sepracor Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009093747-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090005457-A1 | Solid forms comprising (-)-O-desmethylvenlafaxine and uses thereof | SUNOVION PHARMACEUTICALS INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2008103461-A2 | SOLID FORMS COMPRISING (-) O-DESMETHYLVENLAFAXINE AND USES THEREOF | SEPRACOR INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | SLC6A2 256/4885SLC6A4 277/4885SLC6A3 139/4885 |
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MTNR1B | SLC6A2 424/4885SLC6A4 709/4885SLC6A3 224/4885 |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | SLC6A2 257/4885SLC6A4 202/4885SLC6A3 253/4885 |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | GPR139, OPRL1, GRIN2C | SLC6A2 140/4885SLC6A4 148/4885SLC6A3 136/4885 |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NPY1R | SLC6A2 305/4885SLC6A4 485/4885SLC6A3 244/4885 |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | GPR139, OPRL1, GRIN2C | SLC6A2 143/4885SLC6A4 152/4885SLC6A3 120/4885 |
| US-20090005457-A1 | Solid forms comprising (-)-O-desmethylvenlafaxine and uses thereof | COMT, SLC6A3, SLC6A2 | SLC6A2 3/4885SLC6A4 4/4885SLC6A3 2/4885 |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | HCRTR2, HCRTR1, NPY1R | SLC6A2 750/4885SLC6A4 1661/4885SLC6A3 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.